1. Williams R, Airey M, Baxter H, et al. Epidemiology of diabetic retinopathy and macular oedema: a systematic review.
Eye (Lond) 2004;18:963-83.
2. Moss SE, Klein R, Klein BE. The 14-year incidence of visual loss in a diabetic population.
Ophthalmology 1998;105:998-1003.
3. Klaassen I, Van Noorden CJ, Schlingemann RO. Molecular basis of the inner blood-retinal barrier and its breakdown in diabetic macular edema and other pathological conditions.
Prog Retin Eye Res 2013;34:19-48.
4. Haller JA, Kuppermann BD, Blumenkranz MS, et al. Randomized controlled trial of an intravitreous dexamethasone drug delivery system in patients with diabetic macular edema.
Arch Ophthalmol 2010;128:289-96.
5. Otani T, Kishi S, Maruyama Y. Patterns of diabetic macular edema with optical coherence tomography.
Am J Ophthalmol 1999;127:688-93.
6. Kim BY, Smith SD, Kaiser PK. Optical coherence tomographic patterns of diabetic macular edema.
Am J Ophthalmol 2006;142:405-12.
7. Sonoda S, Sakamoto T, Yamashita T, et al. Retinal morphologic changes and concentrations of cytokines in eyes with diabetic macular edema.
Retina 2014;34:741-8.
8. Vujosevic S, Torresin T, Berton M, et al. Diabetic macular edema with and without subfoveal neuroretinal detachment: two different morphologic and functional entities.
Am J Ophthalmol 2017;181:149-55.
9. Daruich A, Matet A, Moulin A, et al. Mechanisms of macular edema: beyond the surface.
Prog Retin Eye Res 2018;63:20-68.
10. Seo KH, Yu SY, Kim M, Kwak HW. Visual and morphologic outcomes of intravitreal ranibizumab for diabetic macular edema based on optical coherence tomography patterns.
Retina 2016;36:588-95.
11. Hu Y, Wu Q, Liu B, et al. Comparison of clinical outcomes of different components of diabetic macular edema on optical coherence tomography.
Graefes Arch Clin Exp Ophthalmol 2019;257:2613-21.
13. Bayat AH, Elcioglu MN. Effects of dexamethasone treatment on serous retinal detachment in ranibizumab-resistant diabetic macular edema.
Ther Adv Ophthalmol 2020;12:2515841420971936.
14. Ceravolo I, Oliverio GW, Alibrandi A, et al. The application of structural retinal biomarkers to evaluate the effect of intravitreal ranibizumab and dexamethasone intravitreal implant on treatment of diabetic macular edema.
Diagnostics (Basel). 2020. 10:p. 413.
15. Bonfiglio V, Reibaldi M, Pizzo A, et al. Dexamethasone for unresponsive diabetic macular oedema: optical coherence tomography biomarkers.
Acta Ophthalmol 2019;97:e540-4.
16. van Dijk HW, Verbraak FD, Kok PH, et al. Early neurodegeneration in the retina of type 2 diabetic patients.
Invest Ophthalmol Vis Sci 2012;53:2715-9.
17. Chhablani J, Sharma A, Goud A, et al. Neurodegeneration in type 2 diabetes: evidence from spectral-domain optical coherence tomography.
Invest Ophthalmol Vis Sci 2015;56:6333-8.
18. Ebneter A, Wolf S, Abhishek J, Zinkernagel MS. Retinal layer response to ranibizumab during treatment of diabetic macular edema: thinner is not always better.
Retina 2016;36:1314-23.
19. Kim M, Lee P, Kim Y, et al. Effect of intravitreal bevacizumab based on optical coherence tomography patterns of diabetic macular edema.
Ophthalmologica 2011;226:138-44.
20. Shimura M, Yasuda K, Yasuda M, Nakazawa T. Visual outcome after intravitreal bevacizumab depends on the optical coherence tomographic patterns of patients with diffuse diabetic macular edema.
Retina 2013;33:740-7.
21. Ozdemir H, Karacorlu M, Karacorlu SA. Regression of serous macular detachment after intravitreal triamcinolone acetonide in patients with diabetic macular edema.
Am J Ophthalmol 2005;140:251-5.
22. Demircan A, Ozkaya A, Alkin Z, et al. Comparison of the effect of ranibizumab and dexamethasone implant on serous retinal detachment in diabetic macular edema.
J Fr Ophtalmol 2018;41:733-8.
23. Antcliff RJ, Hussain AA, Marshall J. Hydraulic conductivity of fixed retinal tissue after sequential excimer laser ablation: barriers limiting fluid distribution and implications for cystoid macular edema.
Arch Ophthalmol 2001;119:539-44.
24. Provis JM. Development of the primate retinal vasculature.
Prog Retin Eye Res 2001;20:799-821.
25. Snodderly DM, Weinhaus RS, Choi JC. Neural-vascular relationships in central retina of macaque monkeys (Macaca fascicularis).
J Neurosci 1992;12:1169-93.
27. Hodzic-Hadzibegovic D, Sander BA, Valerius M, Lund-Andersen H. Diabetic macular edema treated with anti-vascular endothelial growth factor: considerations related to nonimprovers.
Ophthalmol Retina 2018;2:1133-42.
28. Dugel PU, Hillenkamp J, Sivaprasad S, et al. Baseline visual acuity strongly predicts visual acuity gain in patients with diabetic macular edema following anti-vascular endothelial growth factor treatment across trials.
Clin Ophthalmol 2016;10:1103-10.
29. Qu-Knafo LM, Fajnkuchen F, Sarda V, et al. Impact of serous retinal detachment on the efficacy of ranibizumab in diabetic macular oedema.
Acta Ophthalmol 2017;95:e434-5.
31. Hsia NY, Lin CJ, Chen HS, et al. Short-term outcomes of refractory diabetic macular edema switch from ranibizumab to dexamethasone implant and the influential factors: a retrospective real world experience.
Front Med (Lausanne) 2021;8:649979.
32. Gillies MC, Lim LL, Campain A, et al. A randomized clinical trial of intravitreal bevacizumab versus intravitreal dexamethasone for diabetic macular edema: the BEVORDEX study.
Ophthalmology 2014;121:2473-81.
33. Hobbs S, Mehta A, Patel A, Das A. Proliferative diabetic retinopathy and diabetic macular edema: are these two different disease processes? A retrospective cross-sectional study. Invest Ophthalmol Vis Sci 2016;57:1592.